The association between antidepressant treatment and brain connectivity in two double-blind, placebo-controlled clinical trials: a treatment mechanism study

Publication date: Available online 24 June 2019Source: The Lancet PsychiatryAuthor(s): Yun Wang, Joel Bernanke, Bradley S Peterson, Patrick McGrath, Jonathan Stewart, Ying Chen, Seonjoo Lee, Melanie Wall, Vanessa Bastidas, Susie Hong, Bret R Rutherford, David J Hellerstein, Jonathan PosnerSummaryBackgroundAntidepressant medications offer an effective treatment for depression, yet nearly 50% of patients either do not respond or have side-effects rendering them unable to continue the course of treatment. Mechanistic studies might help advance the pharmacology of depression by identifying pathways through which treatments exert their effects. Toward this goal, we aimed to identify the effects of antidepressant treatment on neural connectivity, the relationship with symptom improvement, and to test whether these effects were reproducible across two studies.MethodsWe completed two double-blind, placebo-controlled trials of SNRI antidepressant medications with MRI scans obtained before and after treatment. One was a 10-week trial of duloxetine (30–120 mg daily; mean 92·1 mg/day [SD 30·00]) and the other was a 12-week trial of desvenlafaxine (50–100 mg daily; 93·6 mg/day [16·47]). Participants consisted of adults with persistent depressive disorder. Adjusting for sex and age, we examined the effect of treatment on whole-brain functional connectivity. We also examined correlations between change in functional connectivity and improvement in symptoms of depression (24-item Ham...
Source: The Lancet Psychiatry - Category: Psychiatry Source Type: research